Study guide

7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal

Key Takeaways Explain This Topic AI

Diagnostic overshadowing—reflexively attributing physical and neuropsychiatric symptoms to an addiction—is a major cause of preventable mortality in addiction medicine.

Endocrine mimics include thyrotoxicosis (mimicking stimulant toxicity or withdrawal; suppressed TSH) and adrenal crisis (Addisonian crisis, mimicking opioid withdrawal but uniquely featuring hyponatremia and hyperkalemia).

Hypoglycemia is the quintessential metabolic imitator; ethanol directly arrests hepatic gluconeogenesis, mandating immediate point-of-care capillary glucose testing for altered mental status.

Occult neurotrauma, particularly subdural hematoma from unwitnessed falls in alcohol use disorder, mimics intoxication or DTs; focal neurological signs mandate an emergent non-contrast head CT.

Hepatic Encephalopathy presents with asterixis, diurnal sleep-wake reversal, and hyperammonemia, managed with lactulose (titrated to 2-3 soft stools/day) and rifaximin while strictly avoiding sedatives.

Last updated: September 2026

7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal

Quick Answer: Patients with active substance use disorders are at exceptionally high risk for acute medical, metabolic, and neurological emergencies that mimic or co-occur with drug intoxication and withdrawal. The dangerous clinical bias of diagnostic overshadowing occurs when healthcare providers reflexively attribute signs such as tachycardia, diaphoresis, tremor, confusion, or agitation to substance abuse without conducting a rigorous medical evaluation. Crucial mimics include thyrotoxicosis (mimicking stimulant toxicity or alcohol withdrawal; check TSH/free T4), adrenal crisis / Addisonian crisis (mimicking acute opioid withdrawal with vomiting, cramps, and hypotension, but uniquely featuring hyponatremia, hyperkalemia , and lack of piloerection/mydriasis; check cortisol/ACTH), hypoglycemia (mimicking alcohol or sedative intoxication; mandatory immediate fingerstick glucose), subdural hematoma (mimicking DTs or intoxication after unwitnessed falls; mandatory non-contrast head CT), and hepatic encephalopathy (distinguished by asterixis , sleep-wake reversal, and hyperammonemia; treated with lactulose and rifaximin ).

1. The Clinical Imperative of Medical Rule-Out & Diagnostic Overshadowing

In emergency departments, crisis triage units, and addiction treatment centers, patients with substance use disorders (SUD) frequently present in acute distress. The clinical phenomenon of diagnostic overshadowing —the tendency of healthcare clinicians to misattribute physical signs and symptoms to a patient's pre-existing substance use disorder or psychiatric diagnosis—is a leading cause of missed diagnoses, permanent neurological disability, and preventable death. [Altered Patient in Addiction Triage]

  • │
  • ┌────────────────────────┴────────────────────────┐
  • ▼ ▼
  • [TOXICOLOGICAL ETIOLOGY] [MEDICAL / ORGANIC MIMIC]
  • Congruent tox screen • Endocrine (Thyrotoxicosis, Adrenal Crisis)
  • Matched withdrawal timeline • Metabolic (Hypoglycemia, Hepatic Encephalopathy)
  • No focal neuro deficits • Structural / Trauma (Subdural Hematoma, Stroke)
  • Resolves with detox protocol • Systemic / Infection (Sepsis, NCSE, Meningitis)

Every patient presenting with altered mental status, acute autonomic instability, or behavioral dysregulation must undergo a rapid, systematic medical clearance protocol before being transferred to a psychiatric or non-medical addiction facility.

2. Endocrine Mimics of Intoxication and Withdrawal

Endocrine crises can generate dramatic autonomic and neuropsychiatric derangements that precisely mirror sympathomimetic intoxication, sedative withdrawal, or opioid withdrawal.

Thyrotoxicosis and Thyroid Storm vs. Stimulant Toxicity / Severe Alcohol Withdrawal

Pathophysiology: Excess circulating free thyroxine ( T 4 T_4 T 4 ​ ) and triiodothyronine ( T 3 T_3 T 3 ​ ) dramatically upregulate the density and sensitivity of cell-surface beta-adrenergic receptors throughout the cardiovascular and central nervous systems, amplifying endogenously circulating catecholamines.

Shared Clinical Features: Markedly elevated heart rate (resting sinus tachycardia or atrial fibrillation), wide pulse pressure, diffuse diaphoresis, hyperpyrexia, fine kinetic hand tremor, severe anxiety, psychomotor agitation, weight loss, and hyperreflexia.

Distinguishing Diagnostic Features:

Physical Hallmarks: In thyrotoxicosis, the APRN often identifies lid lag , proptosis/exophthalmos (Graves' disease), an enlarged, palpable thyroid gland (goiter with or without vascular bruits), and pretibial myxedema.

Laboratory Workup: Serum Thyroid-Stimulating Hormone (TSH) is profoundly suppressed ( < 0.01 mIU/L <0.01\text{ mIU/L} < 0.01 mIU/L in primary hyperthyroidism), while Free T 4 T_4 T 4 ​ and Free T 3 T_3 T 3 ​ are markedly elevated. In stimulant toxicity or alcohol withdrawal, TSH is normal.

Toxicology: Qualitative and quantitative urine/serum drug screens are negative for cocaine, amphetamines, cathinones, and alcohol metabolites (unless co-ingested).

Emergency Management: If thyroid storm is unrecognized and the patient is treated solely with withdrawal protocols, high-output cardiac failure and circulatory collapse can ensue. Management requires beta-blockade ( propranolol to control adrenergic excess and block peripheral T 4 T_4 T 4 ​ -to- T 3 T_3 T 3 ​ conversion), thionamides ( propylthiouracil [PTU] or methimazole ), followed by potassium iodide and glucocorticoids ( hydrocortisone or dexamethasone).

Adrenal Insufficiency & Addisonian Crisis vs. Acute Opioid Withdrawal

Adrenal insufficiency (Addisonian crisis) is one of the most fatal diagnostic mimics in acute addictions care, frequently misdiagnosed as acute opioid withdrawal or severe viral gastroenteritis.

Pathophysiology: Primary destruction of the adrenal cortex (Addison's disease) or secondary suppression of pituitary adrenocorticotropic hormone (ACTH) leads to an acute deficiency of glucocorticoids ( cortisol ) and mineralocorticoids ( aldosterone ). Without aldosterone, the renal distal tubules cannot reabsorb sodium or excrete potassium and hydrogen ions.

Shared Clinical Features: Severe nausea, intractable projectile vomiting, diffuse cramping abdominal pain, explosive diarrhea, profound anorexia, diffuse myalgias, arthralgias, tachycardia, and extreme physical exhaustion.

Crucial Distinguishing Physical Signs:

Absence of Opioid Withdrawal Hallmarks: An Addisonian crisis lacks the classic objective sympathetic signs of opioid withdrawal: there is no piloerection ("gooseflesh"), no mydriasis (pupils are normal or small), no yawning , no rhinorrhea , and no lacrimation .

Cutaneous Hyperpigmentation: In primary adrenal insufficiency, lack of cortisol negative feedback drives pro-opiomelanocortin (POMC) gene transcription in the anterior pituitary. POMC is cleaved into ACTH and melanocyte-stimulating hormone (MSH) , producing distinctive bronze, slate-gray hyperpigmentation of the palmar creases, extensor surfaces (elbows, knees), vermilion border of the lips, and buccal mucosa.

Cardiovascular Collapse: While opioid withdrawal causes moderate systolic hypertension and tachycardia, adrenal crisis produces severe, progressive orthostatic hypotension rapidly advancing to refractory hypovolemic shock.

Hallmark Laboratory Dissociation:

Adrenal Crisis: Serum chemistry reveals severe hyponatremia ( N a + < 130 mEq/L Na^+ < 130\text{ mEq/L} N a + < 130 mEq/L ) accompanied by hyperkalemia ( K + > 5.5 mEq/L K^+ > 5.5\text{ mEq/L} K + > 5.5 mEq/L ), metabolic acidosis, and hypoglycemia (due to cortisol deficiency blunting hepatic gluconeogenesis).

Opioid Withdrawal: Serum electrolytes are typically normal; if deranged, dehydration produces hypernatremia or prerenal azotemia (elevated BUN/creatinine) with normal potassium.

Definitive Diagnostic & Resuscitation Interventions: Draw a random serum cortisol and plasma ACTH immediately. A baseline serum cortisol < 3 μ g/dL <3\ \mu\text{g/dL} < 3 μ g/dL in a stressed, hypotensive patient confirms adrenal failure. Administer immediate intravenous hydrocortisone (100 mg IV bolus followed by 50–100 mg every 6 hours) combined with aggressive volume resuscitation using 0.9% normal saline with 5% dextrose ( D 5 N S D_5NS D 5 ​ NS ). Do not wait for lab confirmation to initiate hydrocortisone if crisis is suspected.

Hypoglycemia: The Great Metabolic Chameleon

Pathophysiology in Addictions: Ethanol is metabolized in hepatocytes by alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH), converting oxidized nicotinamide adenine dinucleotide ( N A D + NAD^+ N A D + ) to reduced N A D H NADH N A DH . In malnourished individuals with depleted hepatic glycogen stores (common in chronic AUD), the resulting profound depletion of N A D + NAD^+ N A D + directly arrests hepatic gluconeogenesis (by preventing the conversion of lactate to pyruvate and malate to oxaloacetate). This produces life-threatening alcoholic hypoglycemia .

Shared Clinical Features: Diaphoresis, coarse hand tremor, tachycardia, dizziness, slurred speech, wide-based gait ataxia, severe confusion, combativeness, progressing to seizures and coma—frequently dismissed as acute ethanol intoxication or sedative overdose.

Clinical Mandate: Any patient presenting with altered mental status, drowsiness, or aggressive confusion must have an immediate point-of-care capillary fingerstick blood glucose check. If blood glucose is < 70 mg/dL <70\text{ mg/dL} < 70 mg/dL (and especially < 50 mg/dL <50\text{ mg/dL} < 50 mg/dL ), administer immediate IV dextrose. In chronic alcohol users, always administer intravenous thiamine (100–500 mg) prior to or concurrently with intravenous glucose to prevent precipitating acute Wernicke's encephalopathy .

Pheochromocytoma vs. Cocaine / Methamphetamine Toxicity

Pathophysiology: Rare neuroendocrine chromaffin-cell tumor of the adrenal medulla that autonomously secretes paroxysmal surges of norepinephrine, epinephrine, and dopamine.

Shared Clinical Features: Episodic paroxysms ("spells") consisting of the classic triad: severe pounding headache, generalized drenching diaphoresis, and severe resting palpitations/tachycardia, associated with profound malignant hypertension and a sense of impending doom—virtually indistinguishable from acute cocaine or amphetamine toxicity.

Distinguishing Diagnostic Workup: Negative serial urine/blood toxicology screens during acute attacks; elevated 24-hour urinary fractionated metanephrines and catecholamines or elevated plasma free metanephrines; cross-sectional abdominal CT/MRI demonstrating an adrenal mass.

3. Neurological and Structural Mimics in Acute Addictions

Neurological emergencies in substance-using populations carry exceptionally high mortality if mismanaged as routine withdrawal or intoxication. [CRUCIAL NEUROLOGICAL MIMICS IN ADDICTIONS]

  • │
  • ┌─────────────────────────────┼─────────────────────────────┐
  • ▼ ▼ ▼
  • [Subdural Hematoma (SDH)] [Systemic Delirium / Sepsis] [Hepatic Encephalopathy]
  • Occult falls; coagulopathy • Infection (UTI, Pneumonia) • Flapping tremor (Asterixis)
  • Fluctuating sensorium • Lacks 48-96h DTs timeline • Sleep-wake cycle reversal
  • Lateralizing neuro signs • Leukocytosis, high procal • Portosystemic shunt / ammonia
  • Emergent Non-Contrast CT • Broad-spectrum antibiotics • Lactulose & Rifaximin
  • Subdural Hematoma (SDH) vs. Intoxication & Delirium Tremens

Pathophysiology: Chronic heavy alcohol consumption produces generalized cerebral cortical atrophy (widening the subdural space and placing mechanical tension on bridging cortical veins), accompanied by thrombocytopenia, impaired hepatic synthesis of clotting factors (Factors II, VII, IX, X), and prolonged prothrombin time (PT/INR). Low-impact, unwitnessed falls from alcohol-induced ataxia frequently tear these fragile bridging veins, resulting in a slow venous hemorrhage that accumulates in the subdural space over days to weeks.

Shared Clinical Features: Progressive cognitive clouding, confusion, slurred speech, unsteady gait, lethargy, fluctuating level of consciousness, and agitation.

The Fatal Diagnostic Trap: Medical staff often assume the patient is simply "drunk," experiencing prolonged intoxication, or entering Delirium Tremens. If an intoxicated or withdrawing patient is placed in a detoxification bed or observation holding area without neuroimaging, increasing intracranial pressure (ICP) can cause uncal herniation and death.

Red Flag Neurological Indicators:

Fluctuating consciousness out of proportion to blood alcohol concentration;

Focal / Lateralizing neurological signs: Asymmetric pupils (unilateral pupillary dilation / anisocoria), unilateral facial droop, asymmetric hyperreflexia, unilateral pronator drift, or a positive unilateral Babinski sign;

History of recent head contusion, facial lacerations, or "raccoon eyes" / battle sign.

Clinical Rule: Any patient with a history of alcohol use disorder who presents with altered mental status, head trauma, focal neurological deficits, or failure to clear cognitively as expected mandates an immediate non-contrast head CT scan .

Acute Delirium from Systemic Infection / Sepsis vs. Delirium Tremens (DTs)

The Challenge: Patients with AUD have high rates of occult aspiration pneumonia, urinary tract infections (UTIs), spontaneous bacterial peritonitis (SBP in cirrhotics), cellulitis, and endocarditis (in IV drug users). Both sepsis and DTs present with fever, tachycardia, diaphoresis, and fluctuating delirium.

Differentiating Features:

Timeline: Delirium Tremens has a rigid neurochemical timeline, almost never occurring before 48 hours and peaking between 72 to 96 hours post-cessation of alcohol. In contrast, septic delirium can present at any time, including on Day 0 or Day 1 while blood alcohol is still positive.

Autonomic Storm Profile: DTs is characterized by malignant sympathetic hyperactivity (intense, violent, whole-body tremors, labile systolic hypertension > 180 mmHg >180\text{ mmHg} > 180 mmHg , heart rates > 130 bpm >130\text{ bpm} > 130 bpm , drenching diaphoresis) and terrifying visual hallucinations (zoopsia). Septic delirium often features warm/flushed or mottled skin, progressive hypotension (distributive shock), hypothermia or hyperthermia, and less pronounced motor tremor.

Biomarkers: Marked leukocytosis with left shift, elevated serum lactate ( > 2 mmol/L >2\text{ mmol/L} > 2 mmol/L ), elevated procalcitonin, and abnormal urinalysis point to an infectious etiology.

Hepatic Encephalopathy (HE)

Pathophysiology: Advanced chronic liver disease (cirrhosis) and portosystemic shunting prevent the hepatic conversion of gut-derived neurotoxic ammonia ( N H 3 NH_3 N H 3 ​ ) into urea via the Krebs-Henseleit cycle. Circulating ammonia crosses the blood-brain barrier, where it is converted into glutamine by astrocytic glutamine synthetase. Intracellular accumulation of glutamine causes astrocytic swelling, cerebral edema, cerebral energy depletion, and abnormal GABAergic neurotransmission.

Clinical Staging (West Haven Criteria):

Stage 1: Trivial lack of awareness, shortened attention span, reversal of the diurnal sleep-wake cycle (hypersomnia during day, insomnia at night), mild euphoria or anxiety.

Stage 2: Lethargy, apathy, disorientation to time, subtle personality changes, inappropriate behavior, and prominent asterixis .

Stage 3: Somnolence to semi-stupor, confusion, marked disorientation to place and time, bizarre behavior.

Stage 4: Coma (unresponsive to verbal stimuli).

The Physical Hallmark (Asterixis): Elicited by asking the patient to extend their arms, hyperextend the wrists, and spread their fingers apart with eyes closed. Asterixis manifests as sudden, brief, arrhythmic, involuntary downward "flapping" lapses of the hands caused by intermittent cessation of muscular tone.

Critical Management Principles:

Do NOT administer sedatives: Benzodiazepines and narcotics will precipitate acute Stage 4 hepatic coma.

First-Line Pharmacotherapy: Administer Lactulose (non-absorbable synthetic disaccharide; initial dose 20–30 g [30–45 mL] orally every 1–2 hours until bowel evacuation occurs, then titrate to achieve 2 to 3 soft bowel movements per day ). Lactulose is fermented by colonic bacteria into lactic and acetic acids; the resulting gut acidification converts diffusible ammonia ( N H 3 NH_3 N H 3 ​ ) into non-absorbable ammonium ions ( N H 4 + NH_4^+ N H 4 + ​ ), trapping it in the stool for excretion. Add Rifaximin (550 mg PO BID), a non-absorbable rifamycin antibiotic that selectively suppresses ammonia-producing enteric coliform bacteria.

Non-Convulsive Status Epilepticus (NCSE) & Acute Ischemic / Hemorrhagic Stroke

Non-Convulsive Status Epilepticus (NCSE): Ongoing electrographic seizure activity without generalized tonic-clonic convulsions. Manifests as prolonged stupor, staring spells, subtle rhythmic facial or eyelid twitching, speech arrest, or episodic unresponsiveness. Easily misdiagnosed as post-ictal somnolence, prolonged intoxication, or catatonia. Requires an emergent electroencephalogram (EEG) and IV benzodiazepines.

Cocaine/Methamphetamine-Induced Stroke: Psychostimulants cause acute arterial vasospasm, severe hypertensive spikes, accelerated atherosclerosis, and platelet hyperactivation, precipitating acute ischemic stroke or intracranial/subarachnoid hemorrhage (ruptured berry aneurysms) even in young patients aged 20–40. Sudden-onset unilateral hemiparesis, aphasia, or "thunderclap" headache must never be dismissed as drug intoxication.

4. Comprehensive Medical Mimics Comparison Matrix

Medical Condition Masquerades As (SUD Phenotype) Shared Clinical Signs Definitive Distinguishing Clinical & Lab Findings Definitive Diagnostic & Initial Management Interventions

Thyrotoxicosis / Thyroid Storm Psychostimulant Toxicity; Severe Alcohol/Sedative Withdrawal Tachycardia, fine tremor, diaphoresis, hyperpyrexia, severe anxiety, agitation Lid lag, exophthalmos, goiter ; suppressed TSH ( < 0.01 mIU/L <0.01\text{ mIU/L} < 0.01 mIU/L ), elevated free T 4 / T 3 T_4/T_3 T 4 ​ / T 3 ​ ; negative toxicology screen Check TSH/free T 4 T_4 T 4 ​ ; administer Propranolol (IV/PO), PTU / Methimazole , stress-dose hydrocortisone; supportive cooling.

Adrenal Crisis (Addisonian) Acute Opioid Withdrawal; Severe Gastroenteritis Severe vomiting, diarrhea, diffuse abdominal cramps, tachycardia, weakness Hyponatremia ( N a + < 130 Na^+ < 130 N a + < 130 ), hyperkalemia ( K + > 5.5 K^+ > 5.5 K + > 5.5 ) , hypoglycemia; cutaneous bronze hyperpigmentation; NO piloerection, NO mydriasis ; hypotension/shock Draw random cortisol & ACTH; immediate Hydrocortisone 100 mg IV bolus + IV D 5 N S D_5NS D 5 ​ NS volume resuscitation. Do not delay for lab results.

Hypoglycemia Acute Alcohol Intoxication; Sedative-Hypnotic Overdose Diaphoresis, tremor, slurred speech, ataxia, confusion, combativeness, coma Capillary/serum blood glucose < 70 mg/dL <70\text{ mg/dL} < 70 mg/dL (often < 50 mg/dL <50\text{ mg/dL} < 50 mg/dL ); rapid reversal with glucose administration Immediate fingerstick glucose ; administer IV Thiamine (100–500 mg) followed immediately by D 50 W D_{50}W D 50 ​ W (25–50 mL IV) .

Subdural Hematoma (SDH) Prolonged Intoxication; Delirium Tremens; Encephalopathy Clouding of consciousness, cognitive slowing, ataxia, agitation, confusion Focal neurological signs (anisocoria, unilateral weakness, pronator drift, Babinski); history of falls; failure to clear with detox Emergent non-contrast head CT scan ; urgent neurosurgical consultation for burr-hole evacuation or craniotomy if mass effect/midline shift.

Hepatic Encephalopathy Delirium Tremens; Sedative Intoxication; Dementia Confusion, disorientation, lethargy, cognitive fragmentation, motor tremor Asterixis (flapping tremor on wrist extension); reversed sleep-wake cycle ; fetor hepaticus; jaundice, ascites; elevated serum ammonia Serum ammonia level; Lactulose (titrate to 2–3 soft stools/day) + Rifaximin 550 mg BID; strictly avoid benzodiazepines and sedatives.

Sepsis / Severe Infection Delirium Tremens (DTs) Hyperthermia, tachycardia, diaphoresis, disorientation, agitation Lack of 48–96h withdrawal timeline; leukocytosis with left shift, elevated lactate/procalcitonin ; hypothermia/hypotension; focus of infection Blood cultures, CBC, lactate, UA, chest X-ray; broad-spectrum IV antibiotics, crystalloid fluid resuscitation; assess for SBP in cirrhotics.

Non-Convulsive Status Epilepticus Post-ictal Stupor; Catatonia; Severe Sedative Intoxication Prolonged unresponsiveness, confusion, staring spells, impaired awareness Continuous rhythmic eyelid/facial twitching, automatisms; ictal discharges on EEG; rapid return of awareness following IV lorazepam Emergent Electroencephalogram (EEG) ; IV Lorazepam (2–4 mg) and antiepileptic therapy (IV Levetiracetam or Fosphenytoin).

5. Structured Emergency Medical Clearance Algorithm for Altered Patients

To ensure complete patient safety and eliminate diagnostic overshadowing, the APRN utilizes the following standardized emergency medical clearance pathway: PATIENT PRESENTING ALTERED OR DYSREGULATED

  • │
  • ▼
  • [STEP 1: Immediate Bedside Triage & Vital Signs Evaluation]
  • Temperature (hypothermia vs hyperpyrexia >38.5°C)
  • Heart rate & rhythm (sinus tachycardia, atrial fibrillation, bradycardia)
  • Blood pressure (hypertensive emergency vs orthostatic shock)
  • Oxygen saturation (hypoxemic encephalopathy: pulse ox <90%)
  • POINT-OF-CARE BLOOD GLUCOSE: If <70 mg/dL → IV Thiamine + D50W
  • │
  • ▼
  • [STEP 2: Rapid Focused Neurological & Physical Examination]
  • Pupils: Symmetry, diameter, light reactivity (asymmetry → intracranial lesion)
  • Focal Deficits: Facial asymmetry, unilateral drift, focal weakness, Babinski sign
  • Motor Phenomena: Coarse withdrawal tremor vs Asterixis (HE) vs rhythmic twitches (NCSE)
  • Stigmata of Trauma: Battle sign, raccoon eyes, scalp hematomas
  • Endocrine Stigmata: Goiter, exophthalmos, cutaneous/palmar bronze hyperpigmentation
  • Opioid Specifics: Piloerection, rhinorrhea, lacrimation, yawning
  • │
  • ▼
  • [STEP 3: Mandatory Core Laboratory Battery]
  • CBC with differential (leukocytosis, severe thrombocytopenia)
  • Comprehensive Metabolic Panel: Na, K, HCO3, BUN, Cr, AST, ALT, Total Bilirubin
  • Check for Adrenal Crisis (Hyponatremia + Hyperkalemia)
  • Check for ALD (AST:ALT > 2:1)
  • Urinalysis & Urine Toxicology (GC-MS / LC-MS)
  • ECG: QTc interval prolongation, arrhythmias, ischemic changes
  • │
  • ▼
  • [STEP 4: Selective Diagnostic Neuroimaging & Special Studies]
  • Order Non-Contrast Head CT IF:
  • Focal neurological deficit present
  • History of recent fall or unwitnessed loss of consciousness
  • Known heavy AUD with persistent or worsening delirium
  • Severe persistent headache or unexplained anisocoria
  • Order Endocrine Panels IF:
  • TSH / Free T4: Unexplained hyperadrenergic state without stimulant use
  • Morning Cortisol / ACTH: Nausea/vomiting/hypotension with Na < 130, K > 5.5
  • Order Continuous Video EEG IF:

- Prolonged unexplained stupor, facial twitching, or staring spells

  • Order Serum Ammonia IF:

- Cirrhosis, asterixis, or day-night sleep reversal present